Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Luminex Announces European Unveiling of its New Sample-to-Answer System at ECCMID

Published: Tuesday, May 06, 2014
Last Updated: Tuesday, May 06, 2014
Bookmark and Share
System's innovative design and ease-of-use will streamline laboratory workflow.

Luminex Corporation has announced that it will unveil its new sample-to-answer system for infectious disease testing, ARIES™ at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

ARIES' scalable throughput, easy to use design, and networked data management software will deliver rapid results with a simple workflow.

The five assay launch menu targeted for the ARIES system will include: Flu A/B and RSV, HSV 1&2, Norovirus and Clostridium difficile (C. diff). Future menu items will be announced at a later date.

"ARIES will revolutionize molecular diagnostic testing with a system that integrates seamlessly into the laboratory," said Russell W. Bradley, senior vice president, corporate development and global marketing. "Enabling laboratories to produce faster results, and better manage their QC and compliance requirements can increase service levels to hospitals and doctors for improved patient care."

The unveiling will take place at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) May 11, 2014 at 11am CEST, booth #23. Russell W. Bradley will introduce the innovative sample-to-answer system, ARIES, and give a short demonstration.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Luminex and Bio-Techne Extend and Expand Partnership
Company expands global distribution of award-winning multiplexing instrumentation.
Friday, October 23, 2015
Luminex Receives FDA Clearance
Company has received clearance for ARIES® System and ARIES® HSV 1&2 Assay.
Thursday, October 08, 2015
Luminex Receives FDA and European Clearance for xTAG® CYP2C19 Kit
New cytochrome P450 2C19 assay helps physicians optimize individual patient care.
Tuesday, September 24, 2013
Luminex Corporation Reports Second Quarter 2013 Results
Achieves milestone selling 10,000th multiplexing analyzer.
Tuesday, July 30, 2013
Luminex Receives FDA and European Clearance for New Version of xTAG® CYP2D6 Kit
Luminex submits xTAG® CYP2C19 kit to FDA for review.
Tuesday, July 16, 2013
Merck and Luminex Corporation Enter Agreement
Collaboration to support patient selection for the clinical development of MK-8931, Merck’s lead investigational medicine for Alzheimer’s disease.
Thursday, July 04, 2013
Luminex Corporation Reports First Quarter 2013 Results
Gained FDA clearance for novel Gastrointestinal Pathogen Panel.
Thursday, May 02, 2013
Luminex Receives FDA Clearance for xTAG Gastrointestinal Pathogen Panel
xTAG® GPP simultaneously tests for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single molecular test.
Tuesday, April 23, 2013
Luminex Corporation Receives U.S. FDA Clearance for MAGPIX® Instrument
Innovative multiplexing instrument for clinical laboratories with simultaneous testing for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single molecular test.
Monday, April 15, 2013
Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
Department of Defense award accelerates development of Luminex bio-threat detection technology program.
Thursday, August 16, 2012
Luminex Awarded $11 Million Contract by DTRA
Department of defense award accelerates development of Luminex bio-threat detection technology program.
Tuesday, August 14, 2012
Luminex and University Hospital of Wales Collaborate During Olympic Games
Cardiff hospital implements xTAG® Gastrointestinal Pathogen Panel for use in public health surveillance activities.
Tuesday, August 07, 2012
Luminex Corporation Announces Agreement to Acquire GenturaDx
Acquisition accelerates development of integrated sample-to-answer system for molecular diagnostics.
Monday, July 09, 2012
Luminex Corporation Expands Life Science and Biodefense Groups
Two dedicated groups advance Luminex leadership in scientific research and public safety.
Thursday, April 26, 2012
Luminex Corporation Completes Acquisition of EraGen Biosciences
Company announces completion of acquisition for $34 million in cash.
Monday, January 02, 2012
Scientific News
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Biomarker Finder Adjusts On the Fly
Rice University scientists build better tool to find signs of disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos